These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
99 related items for PubMed ID: 16099339
1. Cost of AIDS care in Mexico: what are its main individual predictors? Aracena B, Gutiérrez JP, Bertozzi SM, Gertler P. Arch Med Res; 2005; 36(5):560-6. PubMed ID: 16099339 [Abstract] [Full Text] [Related]
2. User fees and access to ARV treatment for persons living with HIV/AIDS: implementation and challenges in Burkina Faso, a limited-resource country. Kouanda S, Bocoum FY, Doulougou B, Bila B, Yameogo M, Sanou MJ, Sawadogo M, Sondo B, Msellati P, Desclaux A. AIDS Care; 2010 Sep; 22(9):1146-52. PubMed ID: 20824567 [Abstract] [Full Text] [Related]
3. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing. Quentin W, König HH, Schmidt JO, Kalk A. Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185 [Abstract] [Full Text] [Related]
4. Resource utilization and costs of treating severe rotavirus diarrhea in young Mexican children from the health care provider perspective. Granados-García V, Velázquez-Castillo R, Garduño-Espinosa J, Torres-López J, Muñoz-Hernández O. Rev Invest Clin; 2009 Oct; 61(1):18-25. PubMed ID: 19507471 [Abstract] [Full Text] [Related]
10. Out-of-pocket costs of AIDS care in China: are free antiretroviral drugs enough? Moon S, Van Leemput L, Durier N, Jambert E, Dahmane A, Jie Y, Wu G, Philips M, Hu Y, Saranchuk P. AIDS Care; 2008 Sep; 20(8):984-94. PubMed ID: 18777223 [Abstract] [Full Text] [Related]
11. Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria. Onwujekwe O, Dike N, Chukwuka C, Uzochukwu B, Onyedum C, Onoka C, Ichoku H. Health Policy; 2009 May; 90(2-3):223-9. PubMed ID: 19036466 [Abstract] [Full Text] [Related]
12. [Facing the HIV/AIDS epidemic in Mexico: the response of the health sector]. Gutiérrez JP, López-Zaragoza JL, Valencia-Mendoza A, Pesqueira E, Ponce-de-León S, Bertozzi SM. Rev Invest Clin; 2004 May; 56(2):242-52. PubMed ID: 15377078 [Abstract] [Full Text] [Related]
13. 'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. Ventelou B, Moatti JP, Videau Y, Kazatchkine M. AIDS; 2008 Jan 02; 22(1):107-13. PubMed ID: 18090398 [Abstract] [Full Text] [Related]
14. [Estimating the costs of health care for patients infected with the human immunodeficiency virus in a university hospital in Catalonia]. Santín Cerezales M, Rovira Forns J, Capdevila Pons O, Podzamczer Palter D, Corbella Virós X, Gudiol Munté F. Rev Clin Esp; 1998 Jul 02; 198(7):429-32. PubMed ID: 9737150 [Abstract] [Full Text] [Related]
18. Examining the production costs of antiretroviral drugs. Pinheiro E, Vasan A, Kim JY, Lee E, Guimier JM, Perriens J. AIDS; 2006 Aug 22; 20(13):1745-52. PubMed ID: 16931939 [Abstract] [Full Text] [Related]
20. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Russell S. Am J Trop Med Hyg; 2004 Aug 22; 71(2 Suppl):147-55. PubMed ID: 15331831 [Abstract] [Full Text] [Related] Page: [Next] [New Search]